1.Development of Chronic Disease Management Service System Based on Smart Mobile Equipment
Journal of Medical Informatics 2017;38(6):13-17
According to the personalized service needs of patients with hypertension,diabetes and other chronic diseases,the paper develops a family self-service health management system based on intelligent terminal devices,introduces the system architecture,functions of each terminal,data communication and other key technologies.This system is able to provide patients and family members with real-time and effective disease prevention knowledge and targeted online medical treatment.
2.Clinical Value of 16-slice Spiral CTA for the Diagnosis of Lower Extremity Arterial Disease
Ronghui LIU ; Baoshan LI ; Weigang LIU
Chinese Journal of Minimally Invasive Surgery 2001;0(05):-
Objective To evaluate the clinical value of 16-slice spiral CTA for the diagnosis of lower extremity arterial disease.Methods A total of 103 patients with arterial disease at the lower extremities were submitted to 16-slice spiral CTA.A scanner with a slice thickness of 5 mm,pitch 1.15 mm,increment 1.0 mm,and overlapping 30% was used.Totally 90-100 ml of contrast agent was injected at a rate of 3 ml/s.The scanning was started with a Smartprep auto-trigger and persisted for 20-30 s.The reconstructed images were reformed by means of maximum intensity projection,volume rendering technique,and multiplanar reformation.Results The reconstructed images of the 103 cases were clearly demonstrated by CTA,which showed arteriosclerotic occlusion in 64 patients,arteriostenosis in 32,aneurysm in 4,and normal vessels in 3.Among the 103 patients,40 received surgical treatment,which confirmed the results of CTA.Conclusion Lesions in the lower extremity arteries can be well demonstrated by 16-slice spiral CTA,which can serve as a pre-surgery screening and evaluation.
3.Targeted therapy for triple-negative breast cancer
Ronghui LI ; Caiwen DU ; Guojun ZHANG
Journal of International Oncology 2012;39(7):519-522
Triple-negative breast cancer(TNBC)is a special subtype of breast cancer which is invalid to endocrine therapy.Anti-Her2 targeted therapies such as herceptin and lapatinib are not suitable to TNBC.At present,conventional chemotherapy is the only way for the medical therapy of TNBC.Thus,searching for novel therapeutic agents for TNBC is one of hot researches of breast cancer.New targeted therapy drugs such as PARP-1 inhibitors,EGFR inhibitors,CXCR4 inhibitors,anti-angiogenesis drugs,Src tyrosine kinase inhibitor,and mTOR inhibitor are being researched.
4.Thinking about the teaching of laboratory diagnosis
Ronghui LI ; Mingxin XU ; Liling YUE
Chinese Journal of Medical Education Research 2012;11(3):324-326
Contents of laboratory diagnosis is complex.Traditional teaching method cannot arouse students' interest in study and the teaching effect is poor. Teachers should choose different teaching emphasis for students in different specialty,increase and decrease theory teaching contents according to the demands of students' future actual work,introduce case analysis,train students' capability of clinical logical thinking,enhance students' perceptual knowledge of theory through the training of experiment skills and using PBL teaching method to make students truly participate in teaching course so as to arouse their enthusiasm,These reforming measures will benefit the improvement of teaching quality.
5.Research progress of mTOR inhibitors in the treatment of breast cancer
Ronghui LI ; Wu MA ; Shulian ZHANG
Cancer Research and Clinic 2015;(9):646-648
Although the treatment has made great progress in breast cancer, there are still many problems. For example, primary or secondary on chemotherapy drug resistance and the limitation of treatment in triple-negative breast cancer. So, targeted therapy has become a new strategy to improve this situation. Previous studies showed that the occurrence of breast cancer may be related to the activation of PI3K/Akt/mTOR signaling pathways, and mTOR is an index to judge the prognosis. Parts of breast cancers can obtain clinical benefit with mTOR inhibitors, and it might be a potential treatment target in breast cancer.
6.Impact of TLR5 and NLRC4 activation on proliferation of different breast cancer cell lines
Wei LI ; Zhaozhen ZHUO ; Ronghui LI ; Jun YUAN
Chinese Journal of Immunology 2017;33(6):869-872
Objective:To explore the impact of TLR5 and NLRC4 activation on the proliferation of different breast cancer cell lines,MCF-7 and MDA-MB-23 i.Methods:Induction,expression,purification and identification of recombiant flagellin,including FliC (activating both TLR5 and NLRC4),FliC△90-97 (unable to activate TLR5),FliC-L3A (unable to activate NLRC4),FliC△90-97:L3A (unable to activate both TLR5 and NLRC4).Using different concentration of recombinant flagellin to stimulate MCF-7 and MDA-MB-231 cell lines,72 h later,the proliferation of tumor cells were detected with CCK8.We also used soft AGAR forming experiments to detect the inhibition ratio of recombinant flagellin on breast cancer cell lines.Briefly,1 000 cells were plated in the 6-well plate,then stimulated with 1 μg/ml recombinant flagellin,14 days later,the number of cloning were counted after crystal violet staining.Results:After stimulation with four recombinant flagellins at the concentration of 0.1 μ,g/ml,the inhibition ratio on MCF-7 reached 30%,and FliC△90-97 were dose-dependent on the inhibition of MCF-7 proliferation.At the concentration of 1 μg/ml,FliC-L3A which only activated TLR5 showed stronger inhibition ratio than FliC.FliC△90-97:L3A which did not activate both TLR5 and NLRC4 also inhibited the proliferation of MCF-7.After adding transfection reagent,four recombinant flagellins showed inhibition effect on MDA-MB-231.Conclusion:Flagellin can inhibit the proliferation of MCF-7 and MDA-MB-231,and the mechanism of inhibition on the proliferation were not TLR5 and NLRC4 pathway dependent.There might exist new mechanisms to explain this phenomenon.
7.Radioligand binding assay of insulin receptor in rabbit kidney during ischemia and reperfusion
Tao HE ; Huafu XIE ; Chenggang DUAN ; Ronghui LI ; Zhiqiang FENG
Chinese Journal of Pathophysiology 1989;0(05):-
AIM: To observe the change of insulin receptor in rabbit kidney with acute ischemic-reperfusion injury. METHODS: 15 Japanese white rabbits were allocated randomly into control group, ischemic-reperfusion group(IR group). IR group received clamping for 1 h followed by 2 h or 48 h of reperfusion. At 2 h or 48 h after reperfusion, glucose and insulin in serum were determined. Insulin receptor in renal tissue was analyzed by radioligand binging assay(BAD). RESULTS: The level of serum glucose increased after 2 h reperfusion in 2 groups, but in IR group the value increased much more higher than those in control groups(P
8.Moxifloxacin in Treatment of Lower Respiratory Tract Infection:Clinical Trials
Yuguang LI ; Ailan ZHANG ; Ronghui WU ; Lijun MA
Chinese Journal of Nosocomiology 2005;0(11):-
OBJECTIVE To evaluate the efficacy and safety of moxifloxacin in treating lower respiratory infection.METHODS Totally 102 patients were enrolled in this study,but 3 cases were infixed or weeded.Fifty cases of trial group were given 400mg of moxifloxacin intravenously,once a day for 7-14 days,49 cases of control group were given 400mg of levofloxacin intravenously,once a day for 7-14 days.RESULTS The clinical efficacious rates of moxifloxacin and levofloxacin were 94.0% and 79.6%,respectively.The bacterial clearance rates of moxifloxacin and levofloxacin were 94.3% and 77.8%,respectively.There was significant difference(P0.05) between two groups.CONCLUSIONS Moxifloxacin injection is an effective and safe antibiotics for the treatment of lower respiratory tract infection.
10.The relationship of Aβ40 ,Aβ42 in CSF and apolipoprotein E genotype in patients with Alzheimer's disease.
Weigang LIU ; Ronghui LIU ; Ling LI ; Ruizhen TIAN ; Na LI ; Yachao QI ; Dawei ZHAO ; Peiyuan LV
Clinical Medicine of China 2010;26(5):449-451
Objective To test amyloid beta protein(Aβ)40 and Aβ42 levels in CSF and apolipoprotein E (ApoE) genotype in patients with Alzheimer's disease(AD) and study whether or not the Aβ is related to the severity of dementia and the genotypes of ApoE.Methods 48 AD patients including 27 cases of mild type and 21 cases of serious type and 35 normal controls were selected.Aβ40 and Aβ42 in CSF and ApoE genotype were analyzed.Results Aβ40 levels were ( 12.3 ±4.6) μg/L,( 11.7 ±4.1 ) μg/L,( 12.6 ±4.9) μg/L and ( 11.0 ±3.7) μg/L(t = 1.377,0.705 and 1.385 ,all the p values were greater than 0.05) and Aβ42 levels were ( 105.3 ±25.4) ng/L,(110.7 ±21.7) ng/L,(96.9 ±23.9) ng/L and (123.5 ±29.6) ng/L(t=3.006,2.832,and 3.488,all the p values less than 0.01 ),in AD group,mild AD group,moderate to serious AD group and normal controls,respectively.Aβ40 levels were (11.9 ± 5.2) μg/L vs.(10.5 ± 3.8) μg/L in AD and controls with ApoEε4(t=0.696,P>0.05) and (12.6 ±4.5) μg/L vs.(11.4 ±3.4) μg/L without ApoEε4(t = 1.008,P>0.05).Aβ42 levels were (99.7 ± 23.8) ng/L vs.( 129.6 ± 31.0) ng/L in AD and controls with ApoEε4( t =1.632,P > 0.05 ) and ( 110.4 ± 28.4) ng/L vs.( 129.6 ± 31.0) ng/L in those without ApoEε4 ( t = 2.110,P <0.05 ).Conclusions The CSF level of Aβ is abnormal in AD,and it is related to the severity of the disease and the ApoE genotypes.